MetLife Investment Management’s Larimar Therapeutics LRMR Stock Holding History

MetLife Investment Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$120K	Buy	26,668 +13,071	+96%	+$52.2K	﹤0.01%	2454
2025 Q4	$51.8K	Sell	13,597 -12,110	-47%	-$47.1K	﹤0.01%	2724
2025 Q3	$83K	Sell	25,707 -652	-2%	-$2.44K	﹤0.01%	2725
2025 Q2	$76.2K	Buy	+26,359	New	+$61K	﹤0.01%	2652
2025 Q1	–	Sell	-18,428	Closed	-$71.3K	–	2807
2024 Q4	$71.3K	Sell	18,428 -6,377	-26%	-$42.1K	﹤0.01%	2706
2024 Q3	$162K	Hold	24,805	–	–	﹤0.01%	2392
2024 Q2	$180K	Buy	24,805 +10,882	+78%	+$83.3K	﹤0.01%	2318
2024 Q1	$106K	Buy	+13,923	New	+$108K	﹤0.01%	2507
2018 Q4	–	Sell	-1,279	Closed	-$179K	–	2584
2018 Q3	$179K	Buy	+1,279	New	+$155K	﹤0.01%	2145

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

MetLife Investment Management's LRMR Position: Q1 2026 in Review

MetLife Investment Management increased its Larimar Therapeutics (LRMR) stake by 96% in Q1 2026, buying an estimated $52.2K and bringing the position to 26,668 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

MetLife Investment Management first reported a position in LRMR in Q3 2018 and has held it in 9 quarters since. The position peaked at $180K in Q2 2024. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

MetLife Investment Management held 26,668 shares of Larimar Therapeutics worth $120K as of Q1 2026.
MetLife Investment Management bought 13,071 Larimar Therapeutics shares in Q1 2026, an estimated $52.2K.
Larimar Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2454 holding.
MetLife Investment Management first reported a position in Larimar Therapeutics in Q3 2018 and has held it in 9 quarters since.
MetLife Investment Management's Larimar Therapeutics position peaked at $180K in Q2 2024.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.